28 January 2022 | What should African countries and the African Medicines Agency be doing to change a harmful dynamic driven largely by perceptions of the risks by sponsors and African people? African people think they are unethically targeted for clinical trials whilst sponsors of clinical trials fear that the risks of doing trials in African countries are much too high. If you consider that the UK Medicines and Healthcare products Regulatory Agency (#MHRA) and the European Medicines Agency (#EMA) are both actively trying to increase their attractiveness and the number of clinical trials done within their borders then Africa certainly needs to do more to improve it's #clinicalresearch environment.  #Pharmaceutical industry leaders have been lamenting the lack of #diversity in clinical trials and the need to address it. So how do you sort out the challenges, both real and perceived, in order to increase buy-in as well as diversity and inclusion in clinical trials and in #globalhealth?   Listen to this in-depth conversation with the Executive Director of the European and Development Countries Clinical Trials Partnership which is investing millions to strengthen the ability of the African clinical research environment to truly serve the needs of the African patient.  #health #africa #clinicaltrials #clinicaltrialdiversity #AfricanMedicinesAgency #EDCTP #AVAREF